Company: LGNZZ
Filing Date: 2025-08-11
Form Type: 8-K
Source: 0001193125-25-177452
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-11
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

In connection with the Offering (as defined below), on August 11, 2025, Ligand Pharmaceuticals Incorporated (the “ Company”), as borrower, entered into a Second Amendment to Credit Agreement (the “ Second Amendment”) with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N. A., as Administrative Agent (as defined therein), which amends that certain Credit Agreement, dated as of October 12, 2023, by and among the Company, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N. A., as Administrative Agent, Swingline Lender and L/C Issuer (each as defined therein) (as amended by that certain First Amendment to Credit Agreement, dated as of July 8, 2024, and the Second Amendment, the “ Credit Agreement”), to permit, among other things, certain cash settlement payments on the Notes (as defined below), subject to customary conditions set forth therein.

References to the terms of the Second Amendment and the Credit Agreement are qualified in their entirety by reference to the full text of the Second Amendment, which is incorporated herein by reference to Exhibit 10.1.